Moreover, multitargeted tyrosine kinase inhibitors like Sunitinib and Sorafenib not only inhibit the vascular endothelial growth factor receptor (VEGFR) but also target PDGFR, demonstrating their efficacy in treating renal cell carcinoma (85) and hepatocellular carcinoma (86). Here, KDR is linked to hereditary clear cell renal cell carcinoma.